Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Æ÷»ó¿¬ºÎÀ°Á¾ÀÇ ¼ö¼úÀû Ä¡·á¿¡ ´ëÇÑ °íÂû Surgical Treatment for the Alveolar Soft Park Sarcoma

´ëÇÑ¿Ü°úÇÐȸÁö 2004³â 66±Ç 1È£ p.50 ~ 55
¾È¼ö¹Î, ¿ÀÁ¤Å¹, ÃÖ½ÂÈÆ,
¼Ò¼Ó »ó¼¼Á¤º¸
¾È¼ö¹Î ( Ahn Soo-Min ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

¿ÀÁ¤Å¹ ( Oh Jung-Tak ) 
¿¬¼¼´ëÇб³ Brain Korea 21 Project for Medical Science
ÃÖ½ÂÈÆ ( Choi Seung-Hoon ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract


Purpose: The aim of this study was to evaluate the clinicopathologic characteristics and the results of surgical treatment for alveolar soft part sarcoma (ASPS)
Methods: The clinicopathologic characteristics and surgical treatment results were analyzed retrospectively by reviewing the medical records of 11 patients and interviewing them. Overall survival (OS) was calculated using the Kaplan-Meier method.
Results: Of the 11 patients, 5 men and 13 women, the median age at diagnosis was 27 years and the mean tumor diameter was 6.0¡¾1.9 cm. Six patients without distant metastasis at the time of diagnosis were treated with radical resection, and the other 5 with distant metastasis underwent palliative surgery or biopsy only, followed by chemo-radiation therapy. The onset of distant metastasis (40.0¡¾13.5 months) was similar to the onset of local recurrence (43.3¡¾22.4 months) after a radical operation. The most common site of metastasis was the lung, followed by the brain and bone. The median survival was 52 months and the 5-year OS was 27.2%. The 2-year OS in stage ¥³ disease was 27.7%. The 5-year OS and the disease free survival among the patients with localized disease were 53.3% and 0%, respectively (P=0.043).
Conclusion: Complete resection is the primary therapeutic option for ASPS. Close, long-term follow-up is recommended in order to detect recurrence, particularly in the lung, bone and brain. Long term survival can be achieved with aggressive surgery for local recurrence and even distant metastasis.

Å°¿öµå

Æ÷»ó¿¬ºÎÀ°Á¾;¼ö¼ú;Àç¹ß;ÀüÀÌ;Alveolar soft part sarcoma;Surgery;Recurrence;Metastasis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS